Brokers Issue Forecasts for Repligen FY2024 Earnings

Repligen Co. (NASDAQ:RGEN) – Research analysts at Leerink Partnrs issued their FY2024 earnings estimates for Repligen in a research report issued to clients and investors on Tuesday, November 12th. Leerink Partnrs analyst P. Souda anticipates that the biotechnology company will earn $1.55 per share for the year. The consensus estimate for Repligen’s current full-year earnings is $1.44 per share. Leerink Partnrs also issued estimates for Repligen’s Q4 2024 earnings at $0.39 EPS, Q1 2025 earnings at $0.39 EPS, Q2 2025 earnings at $0.47 EPS, Q3 2025 earnings at $0.42 EPS, Q4 2025 earnings at $0.52 EPS, FY2025 earnings at $1.80 EPS and FY2026 earnings at $2.47 EPS.

Several other analysts have also commented on the stock. Wolfe Research assumed coverage on shares of Repligen in a research note on Thursday. They set a “peer perform” rating for the company. Royal Bank of Canada reissued an “outperform” rating and set a $205.00 price objective on shares of Repligen in a research note on Thursday, September 26th. Wells Fargo & Company initiated coverage on Repligen in a research report on Tuesday, August 27th. They set an “overweight” rating and a $180.00 target price on the stock. StockNews.com raised Repligen from a “sell” rating to a “hold” rating in a report on Wednesday. Finally, JPMorgan Chase & Co. lifted their price target on Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 31st. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, Repligen has a consensus rating of “Moderate Buy” and an average target price of $190.25.

Repligen Price Performance

NASDAQ RGEN opened at $124.73 on Friday. The company’s 50 day simple moving average is $141.09 and its 200 day simple moving average is $144.48. The firm has a market capitalization of $6.99 billion, a PE ratio of -337.11, a P/E/G ratio of 4.36 and a beta of 0.96. Repligen has a 12 month low of $113.50 and a 12 month high of $211.13. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.65 and a quick ratio of 5.56.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.92%. The company had revenue of $154.87 million for the quarter, compared to analyst estimates of $153.34 million. During the same quarter last year, the business earned $0.23 earnings per share. Repligen’s revenue was up 9.7% compared to the same quarter last year.

Institutional Investors Weigh In On Repligen

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. QRG Capital Management Inc. lifted its stake in shares of Repligen by 31.2% in the first quarter. QRG Capital Management Inc. now owns 3,576 shares of the biotechnology company’s stock worth $658,000 after buying an additional 850 shares during the last quarter. Russell Investments Group Ltd. grew its position in shares of Repligen by 5.2% in the first quarter. Russell Investments Group Ltd. now owns 35,134 shares of the biotechnology company’s stock valued at $6,463,000 after purchasing an additional 1,746 shares during the last quarter. State Board of Administration of Florida Retirement System grew its position in shares of Repligen by 4.1% in the first quarter. State Board of Administration of Florida Retirement System now owns 64,035 shares of the biotechnology company’s stock valued at $10,781,000 after purchasing an additional 2,520 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in shares of Repligen by 30.2% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 28,883 shares of the biotechnology company’s stock worth $5,312,000 after purchasing an additional 6,705 shares during the last quarter. Finally, Nicolet Advisory Services LLC grew its holdings in Repligen by 55.4% in the 1st quarter. Nicolet Advisory Services LLC now owns 2,249 shares of the biotechnology company’s stock valued at $409,000 after buying an additional 802 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Repligen

In other news, Director Anthony Hunt sold 22,191 shares of the stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the transaction, the director now owns 139,840 shares of the company’s stock, valued at approximately $20,328,540.80. This represents a 13.70 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 1.20% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.